Learn more about our positive long-term MARINA-OLEā„¢ del-desiran (AOC 1001) data including vHOT video and patient testimonials

Troy Wilson, PhD, JD

Troy Wilson is a successful, serial entrepreneur with a passion to build exceptional companies that create significant value for patients, employees and shareholders. He co-founded Avidity Biosciences (NASDAQ: RNA) and has served as chairman of our board of directors since our inception. Dr. Wilson currently serves as President and Chief Executive Officer and Chairman of Kura Oncology (NASDAQ: KURA).  Previously, he co-founded and served as President and CEO of Araxes Pharma LLC and Wellspring Biosciences, where he and his team pioneered the discovery and development of small molecules inhibitors of the KRAS oncoprotein.  Earlier in his career, Dr. Wilson co-founded and served as President and CEO of Intellikine, a private biopharmaceutical company, acquired by Takeda Pharmaceutical Company Limited in 2011, and he co-founded and served as chief business officer of Ambrx (NASDAQ: AMAM), acquired by Johnson & Johnson Innovative Medicines in 2024. Dr. Wilson holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.